Scout | Discovery and Development of Oral Small-molecule Direct-acting Antivirals Targeting Viruses of Pandemic Potential

This opportunity is no longer accepting applications.

grant

Discovery and Development of Oral Small-molecule Direct-acting Antivirals Targeting Viruses of Pandemic Potential

This grant opportunity supports focused antiviral drug discovery efforts aimed at key viral pathogens and common drug targets to build a robust pipeline of antiviral candidates. The goal is to quickly deploy drug options during viral outbreaks or pandemics. There will be 3-5 awards given. Phase I provides up to $500,000 for up to 1 year, and Phase II offers up to $2,000,000 for up to 3 years. …

Source

Agency: National Institutes of Health

Program: SBIR

Dates

Opportunity Released: August 2, 2024

Open for Submission: August 2, 2024

Application Window Closes: October 18, 2024

Keywords

pandemic potential

small-molecule antivirals

drug discovery

antiviral drug candidates

oral antivirals

NIAID

viral pathogens

outpatient treatment

clinical trials

antiviral pipeline

Supporting Links

Documents

Similar Opportunities

Unlock similar opportunities

Get the full picture on this opportunity

Create a free Scout account to unlock everything you need to decide fast and win the grant.

Instant Fit Analysis

Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
Deep agency & funder detail

Program context, sub-agency structure, and a full eligibility breakdown.
Source links & full documents

Jump straight to the solicitation and download every attachment.
Similar opportunities

Discover related funding matched to your work.

Get a Demo Sign Up

Already have an account? Sign In

Trusted by 500+ Happy Customers